Juno Therapeutics Stock Price, News & Analysis (NASDAQ:JUNO)

$45.60 -3.15 (-6.46 %)
(As of 01/17/2018 01:07 PM ET)
Previous Close$48.75
Today's Range$44.13 - $48.99
52-Week Range$18.90 - $63.45
Volume5.46 million shs
Average Volume1.99 million shs
Market Capitalization$7.72 billion
P/E Ratio-13.45
Dividend YieldN/A
Beta2.32

About Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics logoJuno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Receive JUNO News and Ratings via Email

Sign-up to receive the latest news and ratings for JUNO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:JUNO
CUSIPN/A
Phone+1-206-5821600

Debt

Debt-to-Equity Ratio0.01%
Current Ratio4.77%
Quick Ratio4.77%

Price-To-Earnings

Trailing P/E Ratio-13.4513274336283
Forward P/E Ratio-11.34
P/E GrowthN/A

Sales & Book Value

Annual Sales$79.36 million
Price / Sales65.60
Cash FlowN/A
Price / CashN/A
Book Value$10.18 per share
Price / Book4.48

Profitability

Trailing EPS($3.39)
Net Income$-245,580,000.00
Net Margins-332.05%
Return on Equity-32.54%
Return on Assets-24.87%

Miscellaneous

Employees553
Outstanding Shares114,170,000

Juno Therapeutics (NASDAQ:JUNO) Frequently Asked Questions

What is Juno Therapeutics' stock symbol?

Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."

How were Juno Therapeutics' earnings last quarter?

Juno Therapeutics Inc (NASDAQ:JUNO) announced its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.07. The biopharmaceutical company had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The firm's revenue for the quarter was up 115.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.57) EPS. View Juno Therapeutics' Earnings History.

When will Juno Therapeutics make its next earnings announcement?

Juno Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Juno Therapeutics.

Where is Juno Therapeutics' stock going? Where will Juno Therapeutics' stock price be in 2018?

16 analysts have issued 12 month price objectives for Juno Therapeutics' stock. Their predictions range from $23.73 to $65.00. On average, they anticipate Juno Therapeutics' stock price to reach $49.91 in the next year. View Analyst Ratings for Juno Therapeutics.

What are Wall Street analysts saying about Juno Therapeutics stock?

Here are some recent quotes from research analysts about Juno Therapeutics stock:

  • 1. According to Zacks Investment Research, "Juno company suffered a huge setback with discontinuation of the development of cancer candidate, JCAR015, due to the toxicity witnessed in a phase II ROCKET study in July 2016. Though the company remains on track with its pipeline, candidates are still a few steps away from approval and hence, any setback would weigh heavily on the stock. Also, increased competition in the immunotherapy space is a matter of concern for the company. However, the company’s deal with Celgene for global development and commercialization of immunotherapies is encouraging. Moreover, the company’s targeted, cancer immunotherapy is a highly lucrative. Shares of the company have also outperformed the industry in the last one year. Estimates have been stable lately ahead of the company’s Q4 earnings release. The company has negative record of earnings surprises in recent quarters." (1/17/2018)
  • 2. Maxim Group analysts commented, "The American Society of Hematology (ASH) is now over, and while we saw bluebird’s (BLUE – $190.95 – Hold) valuation rise to over $9B on strong data in CAR-T and gene therapy, Juno’s valuation has seen a retracement from its pre- ASH peak of $7B, to $5B on what is incremental data for lead CAR candidate JCAR017." (12/13/2017)
  • 3. Cowen Inc analysts commented, "We believe initial data from the Phase I TRANSCEND study indicate that JCAR017 is." (3/30/2017)

Who are some of Juno Therapeutics' key competitors?

Who are Juno Therapeutics' key executives?

Juno Therapeutics' management team includes the folowing people:

  • Howard H. Pien, Independent Chairman of the Board (Age 59)
  • Hans Edgar Bishop, President, Chief Executive Officer, Director (Age 52)
  • Sunil Agarwal M.D., President of Research & Development (Age 47)
  • Steven D. Harr M.D., Chief Financial Officer, Head of Corporate Development (Age 46)
  • Hyam I. Levitsky M.D, Executive vice president - Research, chief scientific officer (Age 54)
  • Robert W. Azelby, Executive Vice President, Chief Commercial Officer (Age 49)
  • Ann Lee Ph.D., Executive Vice President - Technical Operations
  • Patrick Y. Yang, Executive Vice President (Age 69)
  • Cynthia Elkins, Chief Information Officer
  • Bernard J. Cassidy, General Counsel, Secretary (Age 62)

When did Juno Therapeutics IPO?

(JUNO) raised $153 million in an IPO on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager.

Who owns Juno Therapeutics stock?

Juno Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BAILLIE GIFFORD & COMPANY (9.24%), BRATTON DOUGLAS K (6.70%) and Wasatch Advisors Inc. (0.55%). Company insiders that own Juno Therapeutics stock include Anthony B Evnin, Bernard J Cassidy, Douglas K Bratton, Hans Edgar Bishop, Hyam Levitsky, Jay T Flatley, Richard Klausner, Robert Azelby, Steve Harr and Sunil Agarwal. View Institutional Ownership Trends for Juno Therapeutics.

Who sold Juno Therapeutics stock? Who is selling Juno Therapeutics stock?

Juno Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc.. Company insiders that have sold Juno Therapeutics company stock in the last year include Bernard J Cassidy, Douglas K Bratton, Richard Klausner, Robert Azelby, Steve Harr and Sunil Agarwal. View Insider Buying and Selling for Juno Therapeutics.

How do I buy Juno Therapeutics stock?

Shares of Juno Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Juno Therapeutics' stock price today?

One share of Juno Therapeutics stock can currently be purchased for approximately $45.60.

How big of a company is Juno Therapeutics?

Juno Therapeutics has a market capitalization of $7.72 billion and generates $79.36 million in revenue each year. The biopharmaceutical company earns $-245,580,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis. Juno Therapeutics employs 553 workers across the globe.

How can I contact Juno Therapeutics?

Juno Therapeutics' mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The biopharmaceutical company can be reached via phone at +1-206-5821600.


MarketBeat Community Rating for Juno Therapeutics (JUNO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  559
MarketBeat's community ratings are surveys of what our community members think about Juno Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Juno Therapeutics (NASDAQ:JUNO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.442.402.472.38
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $49.91$48.06$39.12$30.88
Price Target Upside: 9.45% upside5.04% upside10.29% downside27.62% upside

Juno Therapeutics (NASDAQ:JUNO) Consensus Price Target History

Price Target History for Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ:JUNO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2018Wells Fargo & CoReiterated RatingMarket Perform$54.00 -> $63.00HighView Rating Details
1/11/2018Raymond James FinancialReiterated RatingBuyMediumView Rating Details
1/11/2018JPMorgan Chase & Co.Reiterated RatingHoldHighView Rating Details
1/5/2018Needham & Company LLCInitiated CoverageBuy -> Buy$65.00MediumView Rating Details
12/13/2017Maxim GroupSet Price TargetBuy$56.00HighView Rating Details
11/3/2017CowenReiterated RatingBuyN/AView Rating Details
11/2/2017Leerink SwannReiterated RatingOutperform -> In-Line$34.00 -> $56.00N/AView Rating Details
11/2/2017WedbushReiterated RatingOutperform$42.00 -> $64.00N/AView Rating Details
11/2/2017SunTrust BanksUpgradeHold -> BuyN/AView Rating Details
10/31/2017CitigroupReiterated RatingBuy$59.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral -> Neutral$44.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$27.00 -> $43.00N/AView Rating Details
9/6/2017BarclaysInitiated CoverageOverweight$55.00MediumView Rating Details
8/31/2017Standpoint ResearchReiterated RatingBuy -> ReduceMediumView Rating Details
8/28/2017BTIG ResearchUpgradeSell -> NeutralHighView Rating Details
5/18/2017FBR & CoReiterated RatingHoldMediumView Rating Details
2/27/2016Deutsche BankInitiated CoverageBuyN/AView Rating Details
2/17/2016GuggenheimUpgradeNeutral -> BuyN/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Juno Therapeutics (NASDAQ:JUNO) Earnings History and Estimates Chart

Earnings by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ JUNO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($1.01)N/AView Earnings Details
11/1/2017Q3 2017($0.80)($0.73)$18.12 million$44.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.72)($0.96)$15.59 million$21.30 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.70)($0.71)$16.00 million$19.30 millionViewListenView Earnings Details
3/1/2017Q416($0.61)($0.65)$14.57 million$21.15 millionViewListenView Earnings Details
11/9/2016Q316($0.52)($0.57)$10.98 million$20.80 millionViewListenView Earnings Details
8/4/2016Q216($0.41)($0.64)$14.26 million$27.60 millionViewListenView Earnings Details
5/9/2016Q116($0.52)($0.78)$4.83 million$9.80 millionViewListenView Earnings Details
2/29/2016Q415($0.54)($0.53)$4.79 million$4.15 millionViewListenView Earnings Details
11/10/2015Q315($0.41)($0.53)$6.41 million$1.60 millionViewListenView Earnings Details
8/12/2015Q215($0.37)($0.35)$2.03 million$12.50 millionViewListenView Earnings Details
5/11/2015Q115($0.35)($0.30)ViewListenView Earnings Details
3/18/2015Q414($0.33)($1.73)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Juno Therapeutics (NASDAQ:JUNO) Earnings Estimates

2018 EPS Consensus Estimate: ($4.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.00)($1.00)($1.00)
Q2 20181($0.97)($0.97)($0.97)
Q3 20181($0.99)($0.99)($0.99)
Q4 20181($1.09)($1.09)($1.09)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Juno Therapeutics (NASDAQ:JUNO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Juno Therapeutics (NASDAQ JUNO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.08%
Institutional Ownership Percentage: 69.94%
Insider Trades by Quarter for Juno Therapeutics (NASDAQ:JUNO)
Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ JUNO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/8/2018Richard KlausnerDirectorSell12,724$48.21$613,424.04741,499View SEC Filing  
12/21/2017Richard KlausnerDirectorSell36,000$44.76$1,611,360.00744,392View SEC Filing  
12/21/2017Steve HarrCFOSell8,750$44.76$391,650.00772,082View SEC Filing  
12/18/2017Robert AzelbyEVPSell1,816$44.96$81,647.3670,832View SEC Filing  
11/2/2017Robert AzelbyEVPSell6,666$54.95$366,296.7079,998View SEC Filing  
10/2/2017Sunil AgarwalInsiderSell7,285$44.76$326,076.60View SEC Filing  
9/14/2017Bernard J CassidyGeneral CounselSell28,000$44.92$1,257,760.0055,970View SEC Filing  
9/13/2017Robert AzelbyEVPSell12,850$44.95$577,607.5037,439View SEC Filing  
9/7/2017Richard KlausnerDirectorSell12,000$42.66$511,920.00783,536View SEC Filing  
8/29/2017Robert AzelbyEVPSell12,869$39.95$514,116.5550,289View SEC Filing  
8/7/2017Richard KlausnerDirectorSell12,000$30.34$364,080.00788,985View SEC Filing  
7/13/2017Douglas K BrattonMajor ShareholderSell8,000,000$27.00$216,000,000.00View SEC Filing  
7/7/2017Richard KlausnerDirectorSell24,000$29.39$705,360.00824,985View SEC Filing  
7/3/2017Steve HarrCFOSell8,750$30.00$262,500.00736,189View SEC Filing  
6/27/2017Steve HarrCFOSell8,750$30.00$262,500.00736,189View SEC Filing  
6/20/2017Anthony B EvninDirectorBuy9,000$24.40$219,600.0066,301View SEC Filing  
5/26/2017Jay T FlatleyDirectorBuy20,000$24.76$495,200.00View SEC Filing  
3/10/2017Anthony B EvninDirectorBuy8,000$22.11$176,880.0056,990View SEC Filing  
11/10/2016Robert AzelbyEVPSell12,921$24.14$311,912.9448,640View SEC Filing  
9/27/2016Hans Edgar BishopCEOSell44,000$33.00$1,452,000.002,490,859View SEC Filing  
9/21/2016Hans Edgar BishopCEOSell84,035$30.28$2,544,579.802,518,537View SEC Filing  
9/8/2016Hans Edgar BishopCEOSell23,042$30.06$692,642.522,541,151View SEC Filing  
6/24/2016Richard KlausnerDirectorSell12,000$40.71$488,520.00846,799View SEC Filing  
6/17/2016Hyam LevitskyEVPSell12,418$42.77$531,117.86117,000View SEC Filing  
6/10/2016Steve HarrCFOSell30,000$43.32$1,299,600.00716,052View SEC Filing  
6/9/2016Hans Edgar BishopCEOSell90,750$46.42$4,212,615.002,704,609View SEC Filing  
5/19/2016Bernard J CassidyGeneral CounselSell3,116$39.03$121,617.4855,511View SEC Filing  
5/18/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00858,799View SEC Filing  
4/19/2016Bernard J CassidyGeneral CounselSell3,200$43.12$137,984.0057,933View SEC Filing  
4/15/2016Richard KlausnerDirectorSell12,000$42.90$514,800.00872,792View SEC Filing  
3/28/2016Anthony B EvninDirectorBuy8,000$36.58$292,640.0050,000View SEC Filing  
3/22/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00882,499View SEC Filing  
3/18/2016Bernard J CassidyGeneral CounselSell3,200$38.18$122,176.0061,865View SEC Filing  
3/4/2016Steve HarrInsiderSell5,000$45.00$225,000.00730,000View SEC Filing  
3/2/2016Richard KlausnerDirectorSell24,000$40.42$970,080.00895,259View SEC Filing  
3/1/2016Douglas K BrattonMajor ShareholderSell8,600,000$39.00$335,400,000.00View SEC Filing  
3/1/2016Steve HarrInsiderSell30,000$37.58$1,127,400.00762,987View SEC Filing  
2/19/2016Bernard J. CassidyGeneral CounselSell3,200$34.50$110,400.0063,683View SEC Filing  
1/19/2016Bernard J. CassidyGeneral CounselSell3,200$33.55$107,360.0066,883View SEC Filing  
12/18/2015Bernard J. CassidyGeneral CounselSell3,200$45.39$145,248.0070,083View SEC Filing  
12/10/2015Steve HarrinsiderSell35,000$46.43$1,625,050.00765,000View SEC Filing  
11/19/2015Bernard J. CassidyGeneral CounselSell3,200$52.97$169,504.0071,200View SEC Filing  
11/13/2015Richard KlausnerDirectorSell12,000$49.51$594,120.00930,499View SEC Filing  
10/19/2015Bernard J. CassidyGeneral CounselSell3,200$49.85$159,520.0074,400View SEC Filing  
10/15/2015Richard KlausnerDirectorSell8,000$50.00$400,000.00942,499View SEC Filing  
10/12/2015Richard KlausnerDirectorSell16,000$50.00$800,000.00950,499View SEC Filing  
9/18/2015Bernard J. CassidyGeneral CounselSell11,850$42.50$503,625.0077,600View SEC Filing  
8/19/2015Bernard J. CassidyGeneral CounselSell11,850$40.15$475,777.5089,450View SEC Filing  
7/17/2015Bernard J CassidyGeneral CounselSell11,850$50.55$599,017.50View SEC Filing  
7/15/2015Richard KlausnerDirectorSell8,000$53.34$426,720.00View SEC Filing  
7/2/2015Douglas K BrattonMajor ShareholderSell40,000$54.75$2,190,000.00View SEC Filing  
6/26/2015Anthony B EvninDirectorSell583,333$48.11$28,064,150.63View SEC Filing  
6/24/2015Bernard J CassidyGeneral CounselSell11,850$51.34$608,379.00View SEC Filing  
6/24/2015Douglas K BrattonMajor ShareholderSell270,000$51.13$13,805,100.00View SEC Filing  
6/23/2015Richard KlausnerDirectorSell8,000$52.29$418,320.00View SEC Filing  
6/18/2015Anthony B EvninDirectorSell583,333$52.88$30,846,649.04View SEC Filing  
12/23/2014Douglas K BrattonMajor ShareholderBuy625,000$24.00$15,000,000.00View SEC Filing  
12/23/2014Hal BarronDirectorBuy100,000$24.00$2,400,000.00View SEC Filing  
12/19/2014Douglas K BrattonMajor ShareholderBuy625,000$25.00$15,625,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Juno Therapeutics (NASDAQ JUNO) News Headlines

Source:
DateHeadline
Pre-Open Movers 01/17: (JUNO) (NEWA) (BLUE) Higher; (ATEN) (HIVE) (OBLN) Lower (more...)Pre-Open Movers 01/17: (JUNO) (NEWA) (BLUE) Higher; (ATEN) (HIVE) (OBLN) Lower (more...)
www.streetinsider.com - January 17 at 11:23 AM
Celgene in talks to buy Juno Therapeutics on heels of Impact dealCelgene in talks to buy Juno Therapeutics on heels of Impact deal
finance.yahoo.com - January 17 at 11:23 AM
Deal Buzz Sends Juno Shares SoaringDeal Buzz Sends Juno Shares Soaring
finance.yahoo.com - January 17 at 11:23 AM
Celgene Needs a Boost, But Juno Isnt ItCelgene Needs a Boost, But Juno Isn't It
finance.yahoo.com - January 17 at 11:23 AM
Junos Stock High on Possible AcquisitionJuno's Stock High on Possible Acquisition
finance.yahoo.com - January 17 at 11:23 AM
3 Stocks to Watch on Wednesday: Adient PLC (ADNT), Interactive Brokers Group, Inc. (IBKR) and Juno Therapeutics Inc (JUNO)3 Stocks to Watch on Wednesday: Adient PLC (ADNT), Interactive Brokers Group, Inc. (IBKR) and Juno Therapeutics Inc (JUNO)
investorplace.com - January 17 at 7:29 AM
Juno Therapeutics (JUNO) Earns Buy Rating from Raymond James FinancialJuno Therapeutics (JUNO) Earns Buy Rating from Raymond James Financial
www.americanbankingnews.com - January 11 at 6:18 PM
Form 4 Juno Therapeutics, Inc. For: Jan 05 Filed by: Barron HalForm 4 Juno Therapeutics, Inc. For: Jan 05 Filed by: Barron Hal
www.streetinsider.com - January 11 at 11:49 AM
Juno Therapeutics (JUNO) Receives "Hold" Rating from JPMorgan Chase & Co.Juno Therapeutics (JUNO) Receives "Hold" Rating from JPMorgan Chase & Co.
www.americanbankingnews.com - January 11 at 8:22 AM
Form 4 Juno Therapeutics, Inc. For: Jan 05 Filed by: Klausner RichardForm 4 Juno Therapeutics, Inc. For: Jan 05 Filed by: Klausner Richard
www.streetinsider.com - January 10 at 11:36 AM
Richard Klausner Sells 12,724 Shares of Juno Therapeutics Inc (JUNO) StockRichard Klausner Sells 12,724 Shares of Juno Therapeutics Inc (JUNO) Stock
www.americanbankingnews.com - January 9 at 9:38 PM
Juno Therapeutics Focused on New Drugs for ImmunotherapyJuno Therapeutics Focused on New Drugs for Immunotherapy
finance.yahoo.com - January 8 at 3:38 PM
Juno Therapeutics Inc (JUNO) Receives Average Rating of "Hold" from BrokeragesJuno Therapeutics Inc (JUNO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 8 at 3:54 AM
Juno Therapeutics Names Cindy Elkins as Chief Information Officer - Business Wire (press release)Juno Therapeutics Names Cindy Elkins as Chief Information Officer - Business Wire (press release)
www.businesswire.com - January 6 at 3:34 PM
JUNO THERAPEUTICS INVESTIGATION by Former Louisiana ... - Business Wire (press release)JUNO THERAPEUTICS INVESTIGATION by Former Louisiana ... - Business Wire (press release)
www.businesswire.com - January 6 at 3:34 PM
Juno Therapeutics (JUNO) Appoints Cindy Elkins as Chief Information OfficerJuno Therapeutics (JUNO) Appoints Cindy Elkins as Chief Information Officer
www.streetinsider.com - January 6 at 9:37 AM
Juno Therapeutics Names Cindy Elkins as Chief Information OfficerJuno Therapeutics Names Cindy Elkins as Chief Information Officer
finance.yahoo.com - January 6 at 9:37 AM
Juno Therapeutics (JUNO) Now Covered by Analysts at Needham & Company LLCJuno Therapeutics (JUNO) Now Covered by Analysts at Needham & Company LLC
www.americanbankingnews.com - January 5 at 7:02 PM
Why Juno Therapeutics Stock Cooled Off in December - Motley FoolWhy Juno Therapeutics Stock Cooled Off in December - Motley Fool
www.fool.com - January 5 at 10:52 AM
$23.86 Million in Sales Expected for Juno Therapeutics Inc (JUNO) This Quarter$23.86 Million in Sales Expected for Juno Therapeutics Inc (JUNO) This Quarter
www.americanbankingnews.com - January 3 at 8:32 PM
Why 2017 Was a Year to Remember for Juno TherapeuticsWhy 2017 Was a Year to Remember for Juno Therapeutics
finance.yahoo.com - January 2 at 3:46 PM
Contrasting Aerie Pharmaceuticals (AERI) & Juno Therapeutics (JUNO)Contrasting Aerie Pharmaceuticals (AERI) & Juno Therapeutics (JUNO)
www.americanbankingnews.com - December 30 at 3:28 AM
What Drives Juno Therapeutics (JUNO) Above 150% This Year - NasdaqWhat Drives Juno Therapeutics (JUNO) Above 150% This Year - Nasdaq
www.nasdaq.com - December 29 at 3:33 PM
ETFs with exposure to Juno Therapeutics, Inc. : December 25, 2017ETFs with exposure to Juno Therapeutics, Inc. : December 25, 2017
finance.yahoo.com - December 25 at 4:14 PM
Insider Selling: Juno Therapeutics, Inc. (JUNO) CFO Sells 8,750 Shares of StockInsider Selling: Juno Therapeutics, Inc. (JUNO) CFO Sells 8,750 Shares of Stock
www.americanbankingnews.com - December 22 at 5:54 PM
Insider Selling: Juno Therapeutics, Inc. (JUNO) Director Sells 36,000 Shares of StockInsider Selling: Juno Therapeutics, Inc. (JUNO) Director Sells 36,000 Shares of Stock
www.americanbankingnews.com - December 22 at 5:38 PM
Orbimed Advisors Llc Buys Clementia Pharmaceuticals Inc, Aetna Inc, Universal Health Services ...Orbimed Advisors Llc Buys Clementia Pharmaceuticals Inc, Aetna Inc, Universal Health Services ...
www.nasdaq.com - December 21 at 3:37 PM
Juno Therapeutics, Inc. (JUNO) EVP Robert Azelby Sells 1,816 SharesJuno Therapeutics, Inc. (JUNO) EVP Robert Azelby Sells 1,816 Shares
www.americanbankingnews.com - December 20 at 6:28 PM
Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing ...Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing ...
www.prnewswire.com - December 20 at 10:59 AM
Biotechs: Not So Darn Scary After AllBiotechs: Not So 'Darn Scary' After All
www.nasdaq.com - December 20 at 10:59 AM
BRIEF-Juno Therapeutics And Thermo Fisher Scientific Announce CAR T Manufacturing PartnershipBRIEF-Juno Therapeutics And Thermo Fisher Scientific Announce CAR T Manufacturing Partnership
www.reuters.com - December 20 at 10:59 AM
Why Juno Therapeutics Stock Fell Last WeekWhy Juno Therapeutics Stock Fell Last Week
finance.yahoo.com - December 19 at 11:19 AM
 Brokerages Expect Juno Therapeutics, Inc. (JUNO) Will Announce Quarterly Sales of $23.86 Million Brokerages Expect Juno Therapeutics, Inc. (JUNO) Will Announce Quarterly Sales of $23.86 Million
www.americanbankingnews.com - December 17 at 7:56 AM
Medicare Rigid Billing System Leaves Gilead Cancer Drug in LimboMedicare Rigid Billing System Leaves Gilead Cancer Drug in Limbo
www.bloomberg.com - December 15 at 3:37 PM
 Brokerages Expect Juno Therapeutics, Inc. (JUNO) to Post -$1.15 Earnings Per Share Brokerages Expect Juno Therapeutics, Inc. (JUNO) to Post -$1.15 Earnings Per Share
www.americanbankingnews.com - December 15 at 3:32 PM
Juno Therapeutics, Inc. (JUNO) Given Consensus Rating of "Hold" by BrokeragesJuno Therapeutics, Inc. (JUNO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 14 at 3:54 AM
Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH - Business Wire (press release)Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH - Business Wire (press release)
www.businesswire.com - December 13 at 3:34 PM
ETFs with exposure to Juno Therapeutics, Inc. : December 13, 2017ETFs with exposure to Juno Therapeutics, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 3:33 PM
Juno Therapeutics, Inc. – Value Analysis (NASDAQ:JUNO) : December 13, 2017Juno Therapeutics, Inc. – Value Analysis (NASDAQ:JUNO) : December 13, 2017
finance.yahoo.com - December 13 at 3:33 PM
This Biotech Stock Seen As Cheapest Among Rivals In Cancer DrugsThis Biotech Stock Seen As Cheapest Among Rivals In Cancer Drugs
finance.yahoo.com - December 13 at 3:33 PM
The Winners and Losers From the 2017 ASH MeetingThe Winners and Losers From the 2017 ASH Meeting
finance.yahoo.com - December 13 at 11:12 AM
Maxim Group Reiterates "$56.00" Price Target for Juno Therapeutics (JUNO)Maxim Group Reiterates "$56.00" Price Target for Juno Therapeutics (JUNO)
www.americanbankingnews.com - December 13 at 9:18 AM
Why This Biotech Stock Is Defying A Hematology-Related PitfallWhy This Biotech Stock Is Defying A Hematology-Related Pitfall
finance.yahoo.com - December 12 at 3:35 PM
Bluebirds Shares Jump on Strong Data for CAR-T TherapyBluebird's Shares Jump on Strong Data for CAR-T Therapy
www.zacks.com - December 12 at 11:22 AM
Juno CEO: Changing the way we treat cancerJuno CEO: Changing the way we treat cancer
finance.yahoo.com - December 12 at 11:22 AM
Juno Therapeutics (JUNO) Buy Rating Reiterated at Raymond James FinancialJuno Therapeutics' (JUNO) Buy Rating Reiterated at Raymond James Financial
www.americanbankingnews.com - December 12 at 9:28 AM
Wells Fargo & Company Lowers Juno Therapeutics (JUNO) to Market PerformWells Fargo & Company Lowers Juno Therapeutics (JUNO) to Market Perform
www.americanbankingnews.com - December 12 at 9:04 AM
Bluebird Bio rallies, Spark Therapeutics craters after unveiling data at ASH meetingBluebird Bio rallies, Spark Therapeutics craters after unveiling data at ASH meeting
www.marketwatch.com - December 11 at 3:32 PM
How Juno Therapeutics Inc’s (JUNO) EPS Dropped -21.6%, Did Its Industry Show Weakness Too?How Juno Therapeutics Inc’s (JUNO) EPS Dropped -21.6%, Did Its Industry Show Weakness Too?
finance.yahoo.com - December 11 at 3:32 PM
What's Causing Juno Therapeutics Shares to Tumble 11.9% TodayWhat's Causing Juno Therapeutics Shares to Tumble 11.9% Today
finance.yahoo.com - December 11 at 3:32 PM

SEC Filings

Juno Therapeutics (NASDAQ:JUNO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Juno Therapeutics (NASDAQ:JUNO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Juno Therapeutics (NASDAQ JUNO) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.